Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
Interventions: Tazemetostat, Nivolumab, Ipilimumab; Drug
Lead sponsor: Susan Chi, MD; Other
Eligibility: 6 Months to 21 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Type 1 Diabetes
Interventions: Extended Wear infusion set, Standard Infusion set, Heparin; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obstructive Sleep Apnea
Interventions: Device: Trial nasal mask (F&P); Device
Lead sponsor: Fisher and Paykel Healthcare; Industry
Eligibility: 22 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: MCLA-129, Osimertinib, Chemotherapy; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more

Conditions: Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)
Interventions: Care4Today® Connect CAD-PAD Mobile Application; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Aurora, Colorado • Jacksonville, Florida • Overland Park, Kansas + 2 more

Conditions: Diet Modification
Interventions: Controlled Lacto-ovo vegetarian diet, Controlled Unprocessed red meat diet, Controlled processed red meat diet; Other
Lead sponsor: Purdue University; Other
Eligibility: 20 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Neuropsychiatric Systemic Lupus Erythematosus
Interventions: Magnetic Resonance Angiography (MRA), Magnetic resonance imaging, MRA, diffusion Imaging, perfusion imaging.; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Kidney Disease (CKD)
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Acute Myeloid Leukemia
Interventions: Tamibarotene, Venetoclax, Azacitidine; Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 10 more

Conditions: Advanced Solid Tumor
Interventions: M0324, Pembrolizumab, mFOLFIRINOX; Biological · Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • San Antonio, Texas

Conditions: Intermittent Claudication, Peripheral Vascular Diseases
Interventions: Treadmill Exercise Training, Arm Ergometry Exercise Training, Usual Care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 90 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Muscular Atrophy, Spinal
Interventions: RO6885247, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Stanford, California • Orlando, Florida • Chicago, Illinois + 3 more

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: focus groups; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Overweight, Quality of Life
Interventions: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food, The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher, Human Performance Institute©; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 21 Years and older
Enrollment: 554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Conditions: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Interventions: TAK-007, Chemotherapy Agents; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Azacitidine, Magrolimab, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Lupus Erythematosus, Healthy
Interventions: JNJ-55920839, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina

Conditions: IgA Nephropathy
Interventions: BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Northridge, California • Denver, Colorado • Orlando, Florida + 6 more

Conditions: Dystonic Cerebral Palsy
Interventions: ITB Titration Protocol, Ventral Dorsal Rhizotomy, Deep Brain Stimulation, Research Assessments and Study Monitoring; Drug · Procedure · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

The Evaluation of a New Nasal Mask for the Treatment of Obstructive Sleep Apnea

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

Effects of Consuming Red Meat on the Gut Microbiota in Young Adults

Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study)

A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)

Development of a Clinical Trial Specific Question Prompt List

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Worksite Wellness Randomized Controlled Trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Intrathecal Baclofen and Pediatric Dystonia